Indication: For use as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants, or so called "histaminic cephalalgia".
Pharmacology: Ergotamine is a vasoconstrictor and alpha adrenoreceptor antagonist. The pharmacological properties of ergotamine are extremely complex; some of its actions are unrelated to each other, and even mutually antagonistic. The drug has partial agonist and/or antagonist activity against tryptaminergic, dopaminergic and alpha adrenergic receptors depending upon their site, and it is a highly active uterine stimulant. It causes constriction of peripheral and cranial blood vessels and produces depression of central vasomotor centers. The pain of a migraine attack is believed to be due to greatly increased amplitude of pulsations in the cranial arteries, especially the meningeal branches of the external carotid artery. Ergotamine reduces extracranial blood flow, causes a decline in the amplitude of pulsation in the cranial arteries, and decreases hyperperfusion of the territory of the basilar artery. It does not reduce cerebral hemispheric blood flow.
Mechanism Of Action: Ergotamine acts on migraine by one of two proposed mechanisms: 1) activation of 5-HT1D receptors located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to vasoconstriction, which correlates with the relief of migraine headache, and 2) activation of 5-HT1D receptors on sensory nerve endings of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release.
Interactions:
DrugBank: Interactions for Ergotamine
Interactions for Ergotamine:
The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.
The pressor effects of ERGOMAR and other vasoconstrictor drugs can combine to cause dangerous hypertension.
Imatinib mesylate (Gleevec) may not be effective at treating ...Dec 21, 2005 News-Medical.net, Mayo Clinic Cancer Center investigators report that imatinib mesylate (GleevecTM), the drug used to treat patients with gastrointestinal stromal cancers (GISTs ...
Dishman to expand EM capacity to 7.2mtJan 12, 2006 Business Standard, Dishman Pharmaceuticals plans to increase installed capacity of its Eprosartan Mesylate (EM) plant from 6. MT to 7.2 MT per month to meet the future demand of ...
Oscient Pharmaceuticals Provides Preliminary Revenues for Fourth ...Jan 9, 2006 Genetic Engineering News, ...quarter revenues of approximately $9.2 million, with approximately $8 million in revenue from its lead product, FACTIVE(R) (gemifloxacin mesylate) tablets, and ...
Bio-IT BriefsJan 12, 2006 Bio-IT World, ...pharmacokinetic profile and potential efficacy of IPI-504 in patients with gastrointestinal stromal tumors (GIST) resistant to Gleevec (imatinib mesylate). ...
Oscient Pharmaceuticals to Present at 24th Annual JPMorgan ...Jan 3, 2006 Genetic Engineering News, CEO, Steven Rauscher, will provide an overview of the Company as well as an update on the market performance of FACTIVE(R) (gemifloxacin mesylate) tablets, the ...
Infinity Initiates Phase I Clinical Trial of IPI-504 for Patients ...Jan 10, 2006 PR Newswire (press release), ...pharmacokinetic profile and potential efficacy of IPI-504 in patients with gastrointestinal stromal tumors (GIST) resistant to Gleevec(R) (imatinib mesylate). ...
Effectiveness of Gleevec® Plus Hydroxyurea for Treatment of ...Dec 22, 2005 Cancer Consultants (press release), ...from the University of Pittsburgh, Dulman, Germany, and Duke University have reported that the combination of Gleevec (imatinib mesylate) plus hydroxyurea ...
Vaccine for Chronic Myeloid Leukemia Active in Patients with ...Jan 5, 2006 Business Wire (press release), ...of positive interim data for a novel vaccine known as VAX100 for patients with persistent chronic myeloid leukemia (CML) while on imatinib mesylate (Gleevec(R ...
New Pharmaceutical Treatment Options in the ElderlyDec 14, 2005 Medscape (subscription) Gemifloxacin mesylate (Factive). Gemifloxacin mesylate, which is given daily (320 mg for 5 to 7 days), is a new fluoroquinolone ...
Drug questionable in some kidney cancersDec 22, 2005 United Press International The drug in question, imatinib mesylate, used to treat patients with gastrointestinal stromal cancers, is said not likely to be effective for patients with high ...
Vaccine Shows Promise Against Residual Chronic Myeloid LeukemiaDec 27, 2005 Cancer Consultants (press release), Use of a cancer vaccine after treatment with Gleevec® (imatinib mesylate) may reduce or eliminate residual leukemia in some patients with chronic myeloid ...
Investigational Drug Shows Promise in Gleevec®-Resistent CMLDec 29, 2005 Cancer Consultants (press release), AMN107 has produced treatment responses in some patients with chronic myeloid leukemia (CML) that does not respond to Gleevec® (imatinib mesylate), as well as ...
Treatment with Gleevec® Continues to Show Benefits in CMLDec 28, 2005 Cancer Consultants (press release), ...to updated study results presented at the 47th annual meeting of the American Society of Hematology (ASH), Gleevec® (imatinib mesylate) produces good long ...
Ramoplanin Demonstrates High Activity Against Wide Array of ...Dec 19, 2005 PharmaLive.com (press release), The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ...
Gleevec® plus Hydroxyurea Beneficial for Some Patients with ...Dec 20, 2005 Cancer Consultants (press release), ...to a recent article published in the Journal of Clinical Oncology, the treatment combination consisting of Gleevec (imatinib mesylate) plus hydroxyurea ...
Desatinib Promising for Patients with CML Who Do Not Respond to ...Dec 23, 2005 Cancer Consultants (press release), ...still in clinical trials, is an effective treatment option for patients with chronic myelogenous leukemia (CML) who do not respond to Gleevec (imatinib mesylate ...
Glivec Seeking to Become First Targeted Treatment for Adult ...Dec 13, 2005 PharmaLive.com (press release), December 13, 2005 – Novartis has submitted a marketing authorization application for Glivec® (imatinib) Known as Gleevec® (imatinib mesylate) tablets in ...
Restless Legs Syndrome Fact SheetDec 14, 2005 Community Dispatch (press release) Dopamine agonists such as pergolide mesylate, pramipexole, and ropinirole hydrochloride may be effective in some patients and are less likely to cause ...
Thank You and Farewell to Dr. WG Speed, IIIDec 15, 2005 About - News & Issues, In the 1960's, Dr. Speed was a key researcher in proving inhaled ergotamine such as Migranal Nasal Spray to be an effective treatment. ...
Home
Copyright phasechange.org 2006.
All Rights Reserved.
